期刊文献+

脂联素及其受体在前列腺癌中的作用和研究进展 被引量:3

Research progresses on the role of adiponectin and its receptors in prostate cancer
暂未订购
导出
摘要 前列腺癌是一种激素相关的恶性肿瘤,其与肥胖在流行病学及分子机制方面的关系密切。脂联素是脂肪细胞合成分泌的一种脂肪细胞因子,以内分泌的形式作用于全身各个器官,有抗炎、胰岛素增敏、抗增殖和促进凋亡等作用。肥胖可造成脂联素水平的降低,而脂联素作用的下降与多种肿瘤的发生有密切联系。研究发现前腺癌患者血清脂联素水平下降,前列腺癌组织中脂联素受体下调,提示脂联素及其受体的功能缺陷可能与前列腺癌的发生、发展有关。该文主要对脂联素和脂联素受体的功能、信号通路及其在前列腺癌诊断、治疗和预后中的作用进行综述。 Prostate cancer is a hormone-associated malignancy and is closely related to obesity in terms of epidemiology and molecular mechanisms. Adiponectin, an adipocytokine produced by adipokine and secreted by adipocyte, exhibits anti-inflammatory, insulin-sensitizing, anti-proliferation, and proapoptosis actions on various organs in an endocrine form. Obesity leads to a decrease in adiponectin level, which is closely associated with the occurrence of many tumors. Studies have showed that prostate cancer patients had lower serum adiponectin levels and decreased expression of adiponectin receptors in tumor tissues, which suggest that functional defects of adiponectin and its receptors may be relevant to the occurrence and development of prostate cancer. This paper reviews adiponectin and its receptors’ functions, signaling pathways, and roles in diagnosis, treatment, and prognosis of prostate cancer.
出处 《上海交通大学学报(医学版)》 CSCD 北大核心 2017年第10期1434-1437,共4页 Journal of Shanghai Jiao tong University:Medical Science
基金 国家自然科学基金(81172450)~~
关键词 前列腺癌 脂联素 肥胖 脂联素受体 脂联素缺陷 prostate cancer adiponectin obesity adiponectin receptors adiponectin deficiency
  • 相关文献

参考文献1

二级参考文献11

  • 1M. Cnop,P. J. Havel,K. M. Utzschneider,D. B. Carr,M. K. Sinha,E. J. Boyko,B. M. Retzlaff,R. H. Knopp,J. D. Brunzell,S. E. Kahn MB ChB.Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex[J].Diabetologia.2003(4)
  • 2Housa D,Vernerova Z,Heracek J, et al.Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer[].Physiological Research.2008
  • 3Amling C L,Kane C J,Riffenburgh R H, et al.Ralationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy[].Urology.2001
  • 4Buschemeyer W C 3rd,Freedland S J.Obestity and prostate cancer: epidemiology and clinical implications[].European Urology.2007
  • 5Hsing,AW,Reichardt,JK,Stanczyk,FZ.Hormones and prostate cancer: current perspectives and future directions[].Prostate.2002
  • 6Wei E K,Giovannucci E,Fuchs C S,et al.Low plasma adi-ponectin levels and risk of colorectal cancer in men:a prospec-tive study[].Journal of the National Cancer Institute.2005
  • 7BUB J D,MIYAZAKI T,IWAMOTO Y.Adiponectin as a growth inhibitor in prostate cancer cells[].Biochemical and Biophysical Research Communications.2006
  • 8Goktas S,Yilmaz MI,Caglar K,et al.Prostate cancer and adiponectin[].Urology.2005
  • 9Chandran M,Phillips S A,Ciaraldi T,et al.Adiponectin: more than just another fat cell hormone[].Diabetes Care.2003
  • 10Fasshauer M,Kralisch S,Klier M,et al.Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes[].Biochemical and Biophysical Research Communications.2003

共引文献3

同被引文献15

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部